AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. The company is headquartered in Lausanne, Vaud and currently employs 133 full-time employees. The company went IPO on 2016-09-23. The firm focuses on precision medicine for neurodegenerative diseases. The company designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The firm's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. The company has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
Follow-Up Questions
Qui est le CEO de AC Immune SA ?
Prof. Dr. Andrea Pfeifer est le Chief Executive Officer de AC Immune SA, il a rejoint l'entreprise depuis 2003.
Quelle est la performance du prix de l'action ACIU ?
Le prix actuel de ACIU est de $3.1, il a increased de 6.93% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de AC Immune SA ?
AC Immune SA appartient à l'industrie Biotechnology et le secteur est Health Care
Quelle est la capitalisation boursière de AC Immune SA ?
La capitalisation boursière actuelle de AC Immune SA est de $311.3M
Est-ce que AC Immune SA est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 6 analystes ont établi des notations d'analystes pour AC Immune SA, y compris 4 achat fort, 4 achat, 1 maintien, 0 vente et 4 vente forte
